Group A streptococcal vaccines
AssigneeUniversity of Tennessee Research Foundation
InventorJames B Dale
Life of this patent
Estimating the term…
Abstract
The present invention provides methods for eliciting an immune response against Group A streptococci, comprising use of recombinant fusion polypeptides, and compositions thereof, that include a multivalent immunogenic portion of at least two immunogenic polypeptides from Group A streptococci M proteins (which are capable of stimulating a protective immune response against Group A streptococci), and a reiterated polypeptide from the immunogenic portion carboxy-terminal to the immunogenic portion, wherein the carboxy-terminal polypeptide is not required to stimulate an immune response against Group A streptococci.
Claims20
A hybrid fusion polypeptide comprising a multivalent immunogenic portion fused to an immunogenic polypeptide that is carboxy-terminal to the multivalent immunogenic portion, which protects the immunogenicity of the multivalent immunogenic portion, wherein the multivalent immunogenic portion comprises six immunogenic amino-terminal polypeptides of Group A streptococcal M protein from six different Group A streptococcal serotypes, wherein the immunogenic polypeptide that is carboxy-terminal to the multivalent immunogenic portion is a reiteration of the immunogenic amino-terminal polypeptide from the amino terminus of the multivalent immunogenic portion, wherein each of the six immunogenic amino-terminal polypeptides is at least 10 amino acids in length;
- and wherein at least one of the six immunogenic amino-terminal polypeptides of the multivalent immunogenic portion is selected from Group A streptococcal serotype 2, serotype 11, serotype 22, and serotype 28.
Dependencies are inferred from the claim text.